Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 265,23 per year only 22,10 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Accepted: Published: Version of record: Issue date: DOI:
Ethics declarations Competing interests The author declares associations with the following companies: Astra-Zeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, NovoNordisk and Sanofi-Aventis (advisory board membership
)
The GLP-1/GIP dual agonist, HRS9531, from Hengrui, reported positive Phase 3 results in weight loss, and is the second (after Innovent) Chinese company to submit marketing authorisation for an obesity asset
doi: 10.1016/j.injury.2022.04.009 90 SunQChenE
)
Therapeutic Efficacy of 4-hydroxyisoleucine in Experimental Rat Model of Demyelination: Neuroprotection Through IGF-1 and GLP-1 Level Restoration
